A non-randomised study investigating the use of multiparametric magnetic resonance imaging (mpMRI) to develop imaging biomarkers that will be used to predict treatment response following radiotherapy for prostate cancer.

Not Applicable

• Conditions: Prostate Cancer; Cancer - Prostate

• Registration Number: ACTRN12621001118897
• Lead Sponsor: The University of Auckland

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-08-23
• Last Update Posted: 9 August 2022

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Male
• Target Recruitment: 10

Inclusion Criteria

Signed, written and informed consent
Biopsy proven localised prostate cancer
>= 18 years of age
Willing and able to comply with all study requirements
Completed MRI safety screening and contrast agent safety screening

Exclusion Criteria

Mentally impaired participants or participants for who obtaining informed consent would be difficult
Unable to undergo an MRI examination or has contraindications to MRI
Inadequate renal function for contrast administration (eGFR threshold according to protocol) at baseline imaging
Participants who are unable or unwilling to remain still in MRI for up to 60 minutes
Prior pelvic radiotherapy
Any prosthetic implants such as metallic hip prostheses that may cause artefacts in the imaging studies
Prescribed ADT

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Response to radiotherapy as assessed by mpMRI[Prior to radiotherapy treatment, 6 and 12 months post radiotherapy treatment]

Secondary Outcome Measures

Name	Time	Method
PSA blood test results, relative to baseline, following radiotherapy[Prior to radiotherapy treatment, 6 and 12 months post radiotherapy treatment];Full Blood Count blood test results, relative to baseline, following radiotherapy[Prior to radiotherapy treatment, 6 and 12 months post radiotherapy treatment];Testosterone concentration blood test results, relative to baseline, following radiotherapy[Prior to radiotherapy treatment, 6 and 12 months post radiotherapy treatment];Response to radiotherapy as assessed by by blood test results[Prior to radiotherapy treatment, 6 and 12 months post radiotherapy treatment];mpMRI signals relative to baseline, following radiotherapy[Prior to radiotherapy treatment, 6 and 12 months post radiotherapy treatment];Features in mpMRI signals relative to baseline, following radiotherapy[Prior to radiotherapy treatment, 6 and 12 months post radiotherapy treatment]